VEGFR2/CD309 Antikörper

Produktnummer ABIN967481

Produktdetails anti-VEGFR2/CD309 Antikörper

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser VEGFR2/CD309 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), Flow Cytometry (FACS)

Marke: BD Pharmingen™

Produktmerkmale: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Sodium azide is a reversible inhibitor of oxidative metabolism, therefore, antibody preparations containing this preservative agent must not be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

Aufreinigung: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: Mouse Flk1 and human IgG1 fusion protein

Klon: Avas 12alpha1

Isotyp: IgG2a kappa

Anwendungsinformationen

Applikationshinweise: For immunohistochemistry application, we recommend to use purified Avas 12alpha1 mAb in our special formulation for immunohistochemistry.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store undiluted at 4° C.

Referenzen für anti-VEGFR2/CD309 Antikörper (ABIN967481)

Kataoka, Takakura, Nishikawa, Tsuchida, Kodama, Kunisada, Risau, Kita, Nishikawa: "Expressions of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells." in: Development, growth & differentiation, Vol. 39, Issue 6, pp. 729-40, (1998) (PubMed).

Nishikawa, Nishikawa, Hirashima, Matsuyoshi, Kodama: "Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages." in: Development (Cambridge, England), Vol. 125, Issue 9, pp. 1747-57, (1998) (PubMed).

Nishikawa, Nishikawa, Kawamoto, Yoshida, Kizumoto, Kataoka, Katsura: "In vitro generation of lymphohematopoietic cells from endothelial cells purified from murine embryos." in: Immunity, Vol. 8, Issue 6, pp. 761-9, (1998) (PubMed).

Hanahan: "Signaling vascular morphogenesis and maintenance." in: Science (New York, N.Y.), Vol. 277, Issue 5322, pp. 48-50, (1997) (PubMed).

Shalaby, Ho, Stanford, Fischer, Schuh, Schwartz, Bernstein, Rossant: "A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis." in: Cell, Vol. 89, Issue 6, pp. 981-90, (1997) (PubMed).

Shalaby, Rossant, Yamaguchi, Gertsenstein, Wu, Breitman, Schuh: "Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice." in: Nature, Vol. 376, Issue 6535, pp. 62-6, (1995) (PubMed).

Millauer, Wizigmann-Voos, Schnürch, Martinez, Møller, Risau, Ullrich: "High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis." in: Cell, Vol. 72, Issue 6, pp. 835-46, (1993) (PubMed).

Details zu VEGFR2/CD309

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Andere Bezeichnung: Flk1 (VEGFR2 Produkte)

Synonyme: CD309 antikoerper, FLK1 antikoerper, VEGFR antikoerper, VEGFR2 antikoerper, 6130401C07 antikoerper, Flk-1 antikoerper, Flk1 antikoerper, Krd-1 antikoerper, Ly73 antikoerper, VEGFR-2 antikoerper, sVEGFR-2 antikoerper, Vegfr-2 antikoerper, FLK-1 antikoerper, flk-1 antikoerper, vegfr-2 antikoerper, KDR antikoerper, FLK/KDR antikoerper, flk1 antikoerper, flk1b antikoerper, kdrb antikoerper, si:busm1-205d10.1 antikoerper, si:ch211-254j6.1 antikoerper, si:ch211-278f21.4 antikoerper, wu:fc31a09 antikoerper, fk52c05 antikoerper, flk antikoerper, kdr antikoerper, kdra antikoerper, vegfr2 antikoerper, vegfr4 antikoerper, vegr2 antikoerper, wu:fk52c05 antikoerper, kinase insert domain receptor antikoerper, kinase insert domain protein receptor antikoerper, vascular endothelial growth factor receptor kdr-like antikoerper, kinase insert domain receptor (a type III receptor tyrosine kinase) antikoerper, kinase insert domain receptor like antikoerper, KDR antikoerper, Kdr antikoerper, LOC100136647 antikoerper, kdr antikoerper, kdrl antikoerper

Hintergrund: The Avas 12alpha1 antibody reacts with fetal liver kinase 1 (Flk-1), a receptor protein tyrosine kinase closely related to CD117 (c-kit) and CD140a (PDGF Receptor alpha chain) of the immunoglobulin superfamily. Flk-1, also known as VEGF Receptor-2 (VEGF-R2), is a receptor for vascular endothelial growth factor (VEGF). It is expressed, at the mRNA and protein levels, on distinct sets of mesoderm during gastrulation and on endothelial cells in embryonic tissues. In vivo and in vitro studies indicate that Flk-1 is required for the embryonic development of vascular endothelial and hematopoietic cells.
Synonyms: VEGF-R2, Ly-73

Pathways: RTK Signalweg, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling